FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

Survodutide

BI 456906

Weight Loss & Metabolic

Survodutide (BI 456906) is a GLP-1/glucagon receptor dual agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates GLP-1 receptors for appetite suppression and glycemic control while engaging glucagon receptors to promote hepatic fat oxidation and increased energy expenditure. It is in Phase 3 clinical trials for both obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Wirkmechanismus

Dual GLP-1/glucagon receptor agonist. Glucagon component drives energy expenditure and hepatic lipid metabolism. Shows promise for MASH.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Research protocols use 0.6mg to 4.8mg weekly with dose escalation.

Forschungsnotizen

Clinical Research Status

Survodutide is in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program), with Boehringer Ingelheim positioning it as a differentiated metabolic therapy. Phase 2 data in obesity showed up to 18.7% body weight loss at 46 weeks with the highest dose tested. The MASH Phase 2 trial demonstrated MASH resolution without worsening fibrosis in up to 83% of patients, among the highest reported rates for any pharmacotherapy.

Key Published Findings

The Phase 2b obesity trial demonstrated dose-dependent weight loss competitive with tirzepatide at comparable timepoints. In MASH, the compound's glucagon-mediated hepatic fat reduction produced histological improvements exceeding those seen with GLP-1 monotherapy. Liver fat reduction measured by MRI-PDFF reached 70-80% relative reduction from baseline, suggesting potent hepatic-specific metabolic effects.

Safety Profile

Gastrointestinal adverse events are common during dose escalation, with nausea reported in 30-45% of patients in higher dose groups. Discontinuation rates due to adverse events were 5-10% in Phase 2, somewhat higher than GLP-1 monotherapy trials. The glucagon component has not produced clinically significant hyperglycemia, though monitoring of hepatic and cardiovascular parameters continues in ongoing trials.

Comparison to Related Compounds

Survodutide shares the GLP-1/glucagon dual mechanism with mazdutide but is differentiated by its stronger MASH development program and higher reported weight loss in Phase 2. Compared to semaglutide's MASH data, survodutide's glucagon component appears to provide superior liver fat reduction. The compound's dual approach may offer advantages over pure GLP-1 agonism for patients with concurrent obesity and liver disease.

Community Observations

Hepatologists view survodutide as one of the most promising pharmacotherapies for MASH given the unmet need and limited approved treatments. The combination of substantial weight loss with direct hepatic fat-reducing effects via glucagon agonism addresses both drivers of MASH progression. Researchers note that the GLP-1/glucagon ratio engineering is critical to maintaining glucose safety while maximizing hepatic and metabolic benefits.

Halbwertszeit

~5 days

Rekonstitution

Bacteriostatic water (BAC)

Lagerung

Lyophilisiert

Refrigerate 2-8C. Protect from light.

Rekonstituierter

Refrigerate 2-8C. Use within 28 days.

Rechtsstatus USA

Research chemical (not FDA-approved)

Auch bekannt als

BI 456906

Häufig gestellte Fragen

Was ist Survodutide?

Survodutide (BI 456906) is a GLP-1/glucagon receptor dual agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates GLP-1 receptors for appetite suppression and glycemic control while engaging glucagon receptors to promote hepatic fat oxidation and increased energy expenditure. It is in Phase 3 clinical trials for both obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Wie wirkt Survodutide?

Dual GLP-1/glucagon receptor agonist. Glucagon component drives energy expenditure and hepatic lipid metabolism. Shows promise for MASH.

Wie ist der regulatorische Status von Survodutide in den USA?

Research chemical (not FDA-approved)

Wie lang ist die Halbwertszeit von Survodutide?

~5 days

Wie wird Survodutide noch genannt?

BI 456906

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen